(Q43924101)

28 November 2017

title

Five-year follow-up of trial of replication-competent adenovirus-mediated suicide gene therapy for treatment of prostate cancer (English)

1 reference

28 November 2017

0 references

1 reference

1 reference

Svend O Freytag

1

1 reference

28 November 2017

Hans Stricker

2

1 reference

28 November 2017

James Peabody

3

1 reference

28 November 2017

Jan Pegg

4

1 reference

28 November 2017

Dell Paielli

5

1 reference

28 November 2017

Benjamin Movsas

6

1 reference

28 November 2017

Kenneth N Barton

7

1 reference

28 November 2017

Stephen L Brown

8

1 reference

28 November 2017

Mei Lu

9

1 reference

28 November 2017

Jae Ho Kim

10

1 reference

28 November 2017

publication date

16 January 2007

1 reference

28 November 2017

1 reference

28 November 2017

volume

15

1 reference

28 November 2017

issue

3

1 reference

28 November 2017

page(s)

636-642

1 reference

Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

28 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300068

7 January 2021

Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300068

7 January 2021

A structured debate: immediate versus deferred androgen suppression in prostate cancer-evidence for deferred treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300068

7 January 2021

A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300068

7 January 2021

Double suicide gene therapy augments the antitumor activity of a replication-competent lytic adenovirus through enhanced cytotoxicity and radiosensitization

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300068

7 January 2021

Efficacy and toxicity of replication-competent adenovirus-mediated double suicide gene therapy in combination with radiation therapy in an orthotopic mouse prostate cancer model

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300068

7 January 2021

Second-generation replication-competent oncolytic adenovirus armed with improved suicide genes and ADP gene demonstrates greater efficacy without increased toxicity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300068

7 January 2021

In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300068

7 January 2021

Phase I/II trial evaluating combined radiotherapy and in situ gene therapy with or without hormonal therapy in the treatment of prostate cancer--a preliminary report

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300068

7 January 2021

Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300068

7 January 2021

Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300068

7 January 2021

A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300068

7 January 2021

Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300068

7 January 2021

Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300068

7 January 2021

Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300068

7 January 2021

Overall survival after prostate-specific-antigen-detected recurrence following conformal radiation therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300068

7 January 2021

Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300068

7 January 2021

Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300068

7 January 2021

Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300068

7 January 2021

Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300068

7 January 2021

Preoperative PSA velocity is an independent prognostic factor for relapse after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300068

7 January 2021

Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300068

7 January 2021

Predictors of mortality after prostate-specific antigen failure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300068

7 January 2021

Natural history of progression after PSA elevation following radical prostatectomy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300068

7 January 2021

Regression of established macroscopic liver metastases after in situ transduction of a suicide gene

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300068

7 January 2021

Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300068

7 January 2021

Generation of an anti-tumour immune response in a non-immunogenic tumour: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoural cytokine expression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300068

7 January 2021

Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300068

7 January 2021

Sex or survival: trade-offs between quality and quantity of life

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300068

7 January 2021

Needle biopsy associated tumor tracking of adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300068

7 January 2021

Association between an oncogene and an anti-oncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300068

7 January 2021

Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300068

7 January 2021

Oncogenic potential of the adenovirus E4orf6 protein

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300068

7 January 2021

Adenoviruses in human cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300068

7 January 2021

Analysis of human tonsil and cancer DNAs and RNAs for DNA sequences of group C (serotypes 1, 2, 5, and 6) human adenoviruses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300068

7 January 2021

Linear regressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300068

7 January 2021

Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MT.6300068

7 January 2021

Identifiers

DOI

10.1038/SJ.MT.6300068

1 reference

28 November 2017

1 reference